In:
Basic & Clinical Pharmacology & Toxicology, Wiley, Vol. 131, No. 2 ( 2022-08), p. 138-148
Abstract:
Ciprofol is a propofol analogue with improved pharmacokinetic properties. A multi‐centre, non‐inferiority trial was conducted to compare the deep sedation properties of ciprofol and propofol with a non‐inferiority margin of 8% in patients undergoing gastroscopy and colonoscopy. In total, 289 patients were randomly allocated for surgery (259 colonoscopy and 30 gastroscopy) at a 1:1 ratio to be given intravenous injections of ciprofol (0.4 mg/kg) or propofol (1.5 mg/kg). The primary outcome was the success rate of colonoscopy defined as colonoscopy completion with no need for an alternative sedative or 〉 5 ciprofol or propofol top up doses within any 15‐min time period. The success rate of colonoscopy was 100% in the ciprofol group vs. 99.2% in the propofol group (mean difference 0.8%, 95% CI: −2.2% to 4.2%). Except for the gastrointestinal lesions found during the gastroscopy and colonoscopy procedures, the occurrence rates of adverse drug reactions in the ciprofol and propofol groups were 31.3% and 62.8%, respectively ( P 〈 0.001). Pain on injection was less common in the ciprofol group (4.9% vs. 52.4%, P 〈 0.001). The outcomes demonstrated that ciprofol was non‐inferior to propofol with regard to successful sedation for gastroscopy or colonoscopy procedures and no obvious important adverse events occurred.
Type of Medium:
Online Resource
ISSN:
1742-7835
,
1742-7843
Language:
English
Publisher:
Wiley
Publication Date:
2022
detail.hit.zdb_id:
2151592-X
detail.hit.zdb_id:
2134679-3
SSG:
15,3